Related Experiment Video
Updated: Jul 3, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
[Primary study on preparation and efficiency of neotype hepatocellular carcinoma-dendritic cell vaccine with SOCS1
Zhan-Pei Liu1, Jie Zhang, Ping Lin
1Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective:
To investigate the effect of SOCS1 expression inhibition on hepatocellular carcinoma-dendritic cell vaccine stimulated by LIGHT.
Methods:
The dendritic cells (DC) were generated from mouse bone marrow (BMDC) by cultured in medium containing rmGM-CSF and rmIL-4. The vaccine cells were prepared by loaded with hepatocellular carcinoma HepA antigen and further treated with or without LIGHT and SOCS1 antisense oligonucleotide (AS1). For detecting the maturity of the vaccine cells, the expression of the cell's surface molecules CD40 and CD86 were measured by FACS, and IL-12 and IL-1 secretion from the cells were determined by ELISA. And the CTL activity, cellular proliferation, IL-6 and TNF-beta secretion levels of the vaccine-stimulated lymphocytes were also assessed for analyzing the immune response of lymphocyte.
Results:
CD40 and CD86 expression of the prepared vaccine cells were obviously enhanced by treatment of LIGHT and AS1, and so were IL-12 and IL-1 (P<0.01). It was also observed that CTL activity, cellular proliferation and IL-6 and TNF-beta secreting levels of lymphocytes that were stimulated by the vaccine cells treated with AS1 were notably enhanced.
Conclusion:
Inhibiting SOCS1 can improve the maturation of hepatocellular carcinoma-DC vaccine cell and can increase its inducing ability of anti-cancer immune response.
